Free Trial
NASDAQ:PTCT

PTC Therapeutics (PTCT) Stock Price, News & Analysis

PTC Therapeutics logo
$48.77 -0.38 (-0.77%)
Closing price 07/3/2025 03:28 PM Eastern
Extended Trading
$48.77 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PTC Therapeutics Stock (NASDAQ:PTCT)

Key Stats

Today's Range
$48.34
$49.25
50-Day Range
$36.19
$52.13
52-Week Range
$29.02
$58.38
Volume
307,079 shs
Average Volume
863,724 shs
Market Capitalization
$3.87 billion
P/E Ratio
7.49
Dividend Yield
N/A
Price Target
$65.00
Consensus Rating
Moderate Buy

Company Overview

PTC Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

PTCT MarketRank™: 

PTC Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 140th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 9 buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    PTC Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about PTC Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for PTC Therapeutics are expected to decrease in the coming year, from ($4.52) to ($4.69) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PTC Therapeutics is 7.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.65.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PTC Therapeutics is 7.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.66.

  • Read more about PTC Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.77% of the float of PTC Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    PTC Therapeutics has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in PTC Therapeutics has recently increased by 6.74%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    PTC Therapeutics does not currently pay a dividend.

  • Dividend Growth

    PTC Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.77% of the float of PTC Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    PTC Therapeutics has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in PTC Therapeutics has recently increased by 6.74%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    PTC Therapeutics has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for PTC Therapeutics this week, compared to 8 articles on an average week.
  • Search Interest

    3 people have searched for PTCT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $266,384.00 in company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of PTC Therapeutics is held by insiders.

  • Read more about PTC Therapeutics' insider trading history.
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTCT Stock News Headlines

Cantor Fitzgerald Has Weak Estimate for PTCT FY2026 Earnings
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
FY2025 EPS Estimates for PTCT Decreased by Cantor Fitzgerald
See More Headlines

PTCT Stock Analysis - Frequently Asked Questions

PTC Therapeutics' stock was trading at $45.14 on January 1st, 2025. Since then, PTCT stock has increased by 8.0% and is now trading at $48.7710.

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings results on Tuesday, May, 6th. The biopharmaceutical company reported $10.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.85 by $9.19. The business's revenue was down 9.6% compared to the same quarter last year.
Read the conference call transcript
.

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

Last Earnings
5/06/2025
Today
7/05/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PTCT
Employees
1,410
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$65.00
High Stock Price Target
$112.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+33.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
15 Analysts

Profitability

Trailing P/E Ratio
7.49
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$363.30 million
Pretax Margin
36.74%

Debt

Sales & Book Value

Annual Sales
$806.78 million
Price / Cash Flow
N/A
Book Value
($14.24) per share
Price / Book
-3.42

Miscellaneous

Free Float
74,898,000
Market Cap
$3.87 billion
Optionable
Optionable
Beta
0.50

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:PTCT) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners